1

CURRICULUM VITAE

NAME: Marcia A. Testa, M.P.H., M.Phil. Ph.D. ACADMIC TITLE: Senior Lecturer on Biostatistics WORK ADDRESS: Biostatistics Building 1-417, 665 Huntington Ave, Harvard T.H. Chan School of Public Health, Boston MA 02115 EDUCATION: 1974 Psychology B.A. Connecticut College, New London, CT 1976 Public Health M.P.H. Yale University School of Medicine (Biostatistics) Dept. of Epidemiology and Public Health New Haven, CT 1977 Epidemiology M.Phil. Yale University Graduate School & Public Health Dept. of Epidemiology and Public Health (Biostatistics) New Haven, CT 1980 Epidemiology Ph.D. Yale University Graduate School & Public Health Dept. of Epidemiology and Public Health (Major – Biostatistics) New Haven, CT

(Minors - Math Statistics & Epidemiology)

ACADEMIC APPOINTMENTS: 1979 - 86 Assistant Professor

Departments of Research in Health Education and Community Medicine Director, Biostatistics Research Center University of Connecticut School of Medicine University of Connecticut Health Center, Farmington, Connecticut

1986 - 87 Associate Professor Departments of Research in Health Education and Community Medicine Director, Biostatistics Research Center University of Connecticut School of Medicine

University of Connecticut Health Center, Farmington, Connecticut 1987 – 90 Associate Clinical Professor (Adjunct)

2

University of Connecticut School of Medicine Departments of Research in Health Education and Community Medicine University of Connecticut Health Center, Farmington, Connecticut

1987 – 99 Faculty Lecturer on Biostatistics

Department of Biostatistics Harvard T.H. Chan School of Public Health Harvard University, Boston Massachusetts

1999 - Senior Lecturer on Biostatistics Department of Biostatistics Harvard T. H. Chan School of Public Health

Harvard University, Boston Massachusetts

OTHER ACADEMIC APPOINTMENTS: 1975 - 77 Associate in Research

Connecticut Cancer Epidemiology Unit Yale University School of Medicine, New Haven CT

1977 - 78 Associate in Research and Teaching Fellow

Department of Epidemiology and Public Health Yale University School of Medicine, New Haven, CT 1979 Visiting Fellow, Laboratory of Theoretical Biology National Cancer Institute, National Institutes of Health, Bethesda, MD 1985 - 86 Assistant to the Vice President for Health Affairs

Information Systems Development Office of the Vice President and Executive Director University of Connecticut Health Center, Farmington, CT 2010 - 2015 Director, Preparedness and Emergency Response Learning Center

(PERLC), Division of Policy Translation and Leadership Development, Harvard T. H. Chan School of Public Health, Boston, MA

2016 - Co-Director, Emergency Preparedness, Research, Evaluation and Practice

(EPREP) Program, Division of Policy Translation and Leadership Development, Harvard T. H. Chan School of Public Health, Boston, MA

3

OTHER PROFESSIONAL APPOINTMENTS (NON-ACADEMIC):

1987 - Board Chairman, Phase V Technologies, Wellesley, MA 2002 - 04 Section Councilor, Statistics Section, American Public Health Association 2005, 2009 Secretary, Statistics Section, American Public Health Association 2004 - 06 Chair Elect, Chair, Past Chair, Statistics Section, American Public Health

Association 2006 - 08 Governing Council, American Public Health Association 2005 - Town of Wellesley Board of Health (Vice Chair), Wellesley, Massachusetts 2016 - Town Meeting Member, Wellesley, Massachusetts 2006 - Massachusetts Association of Health Boards, Executive Committee Member 2016 - Board Chairman, Massachusetts Association of Health Boards COMMITTEE SERVICE: DEPARTMENTAL/SCHOOL AND UNIVERSITY SERVICE: 1988 - MPH Steering Committee Member Harvard Chan 1995 - Co-Director, MPH-QM (Quantitative Methods) Program Harvard Chan 1998 - Executive Continuing and Professional Education Executive Committee Member 2000 - Director, MPH-QM Summer Only Program Harvard Chan

PROFESSIONAL SOCIETIES: Primary Memberships American Public Health Association Positions 1982 - pres. Member1 American Public Health Association 1997 - 2000 Statistics Section Council American Public Health Association 2001 - 02, 08-09 Statistics Sec. Secretary-Elect American Public Health Association 2002 - 03, 09 Statistics Sec. Secretary American Public Health Association 2002 - 05 Statistics Sec. Newsletter Ed. American Public Health Association 2003 - 04 Statistics Sec. Chair-Elect American Public Health Association 2004 - 05 Statistics Sec. Chair American Public Health Association 2006 - 08 Governing Councilor American Public Health Association 2008 Statistics Sec. 100th Anniversary American Public Health Association Committee Chair 1 Member of Epidemiology, Health Informatics and Technology and the Applied Public Health Statistics (formerly, Statistics) Sections.

4

1976 - Member American Statistical Association 1986 - Member American Diabetes Association Other Active Professional Memberships since 2000 or later American Telemedicine Association Association for Health Services Research American Diabetes Association Research Review Board (1997 – 2003) Drug Information Association Health Information and Management Systems Society IEEE Society (Computing Section International Biometrics Society International Society for Pharmacoepidemiology International Society for Quality of Life Research International Society for Pharmacoeconomics and Outcomes Research Massachusetts Association of Health Boards (MAHB) National Association of County and City Health Officials (NACCHO) National Association of Local Boards of Health (NALBOH) International Society for Disease Surveillance (ISDS) Society for Implementation Research Collaboration GRANT REVIEW ACTIVITIES: (Since 2010) 4/2010 iADAPT Comparative Effectiveness AHQR 2011 - 2013 Ad hoc Review Committee2 PCORI 2013 - Elected to PCORI Standing Merit Review Panels: Patient Centered Outcomes Research Institute Cycles, Improving Methods for Conducting Patient-Centered Outcomes (Methods) A = Applied Methods, P = Pure Analytics Methods. Meetings given below: Meeting Date PCORI Merit Review Committee 6/2013 Inaugural Review (Methods - A) 8/2013 August 2013 Cycle (Methods - P) 11/2013 November 2013 Cycle (Methods - P) 5/2014 Winter 2014 Cycle(Methods - P) 8/2014 Spring 2014 Cycle (Methods - P) 2/2015 Fall 2014 Cycle (Methods - P)

2 Various PCORI Merit Review Panels including: Improving Methods for Conducting Patient-Centered Outcomes; Assessment of Prevention, Diagnosis, and Treatment Options (APDTO/CER); Communication and Dissemination Research (CDR); Improving Methods PSH PURE; Partnering for PCORNet, PCORNet

5

5/2015 Winter 2015 (PCOR Net ) 8/2015 Spring 2015 Cycle (Methods - P) 5/2016 Cycle 3 2015 (Methods - P) 3/2017 Cycle 3 2016 (Methods - P) 2/2018 Cycle 2 2017 PaCR (PCORNet) 12/2018 Cycle 2 2018 (Dissemination and Communication) EDITORIAL ROLES: Ad Hoc Reviewer for the following publications: American Journal of Public Health, American Journal of Preventive Medicine, Annals of Epidemiology, Annals of Internal Medicine, BMJ-Open, Diabetes, Diabetes Care, Diabetes and Metabolism, Disaster Medicine, Journal of the American Medical Association, Journal of the American Statistical Association, Journal of Endocrinology and Metabolism, Journal of Public Health Management and Practice, New England Journal of Medicine, Pediatrics, Statistics in Medicine, HONORS AND DISTINCTIONS: Date Name of Honor/Distinction Organization Description of Achievement 1973 Phi Beta Kappa Phi Beta Kappa Highest >1%-tile rank 1973 Student Fellow American Psychological National Research Award Association 1974 Summa cum laude Connecticut College Highest >1%-tile rank 1974 Honors in Psychology Connecticut College Research Achievement 1976 John H. Watkins Thesis Prize Yale University Best MPH Thesis 1993 Roger L. Nichols Excellence Harvard Chan Excellence in Teaching in Teaching Award 1995 Donald E. Francke Award Drug Information Association Best Publication 2008 Statistics Section Award American Public Health Assoc Excellence in Practice 2012 Excellence in Teaching in Harvard Chan Excellence in Teaching Continuing Education Award

6

FUNDED GRANTS AND UNFUNDED PROJECTS: COMPLETED GRANTS (since 1993) 2/1993 - 3/1997 Statistical Methods for Quality-of-Life Outcomes Research AHCPR R01 HS07767-01

Sponsor: Agency for Healthcare Research and Quality (AHRQ) Role: Principal Investigator

Goals: To develop and apply measurement and statistical methods for assessing patient-reported outcomes in comparative clinical trials.

1/1995 - 12/1997 Quality of Life and Cost-Effectiveness Analysis in the Treatment of NIDDM Sponsor: American Diabetes Association Role: Principal Investigator

Goals: To develop and apply measurement and statistical methods for incorporating patient-reported quality of life and health economic outcomes in comparative diabetes clinical trials.

1/1993 - 12/2001 Adult ACTG - Statistical and Data Management Analysis Center

U01 AI38855 Sponsor: National Institutes of Health

Role: Senior Statistician Goals: To assist the AIDS Clinical Trials Group collect, manage and analyze data from clinical trials in HIV-AIDS conducted by the ACTG.

5/1998 – 4/2004 Making Advances in Jaundice (MAJIC) Quality of Care in Newborns R01 HSO 9872-03

Sponsor: Agency for Health Care Policy and Research Role: Senior Statistician

Goals: To benchmark and evaluate the comparative effectiveness and quality of care of programs intended to reduce jaundice in newborns.

9/2004 – 10/2010 Harvard School of Public Health Center for Public Health Preparedness, U90/CCU124242-5

Sponsor: Centers for Disease Control and Prevention (CDC) Role: Co-Investigator and Director, Evaluation Core

Goal: To train and evaluate local, state and federal public health workers in emergency preparedness and response to natural and man-made disasters.

11/2011 – 8/2012 Hazard Vulnerability Analysis to Enhance Public Health Preparedness in

Connecticut

7

Contract #2012-0176 Sponsor: State of Connecticut/Department of Public Health

Role: Principal Investigator Goal: To conduct a hazard vulnerability analysis to aid in developing

prevention and response protocols for natural man-made disasters and emergencies in the State of Connecticut.

Direct: $46,294 Indirect:$3,703 Total $49,997 1/2012 – 5/2012 Local health department barriers to the administration of DHHS

emergency preparedness funds. NACCHO 2012-010903

Sponsor: National Association of County and Health Officials Role: Co-Investigator, Senior Statistician Goal: To analyze local public health survey data to determine barriers to

effectively using emergency preparedness funding from the Public Health Emergency Preparedness federal grants.

9/2008 – 10/2014 Linking Assessment and Measurement to Performance in PHEP Systems

(LAMPS), Harvard Center for Public Health Preparedness 1 P01 TP000307-06

Sponsor: Centers for Disease Control and Prevention (CDC) Role: Co-Investigator and Director, Mentorship Program for Research

Fellows and Head “New Research Investigators and Pilot Projects” Goal: To develop measurement and analytical methods for performance

evaluation in public health emergency preparedness programs. 9/2010 – 12/2015 Harvard School of Public Health Preparedness and Emergency Response

Learning Center (PERLC) 1U90TP000147-05

Sponsor: Centers for Disease Control and Prevention Role: Principal Investigator and Director As part of a national network of 14 PERLCs across the U.S., the Harvard

PERLC to provided training to HHS Regional 1 state, local, and tribal public health authorities within self-defined service areas to meet their unique workforce development needs in the area of public health preparedness and response; specialized training, education, and consultation. National network project were also undertaken in collaboration with the CDC and the other 13 PERLCs.

Direct: $2,314,123 Indirect: $163,236 Total $2,477,359 10/2014 – 1/2015 RICE – RIsk Communication Evaluation Project WHO 014-201090987 Sponsor: World Health Organization (WHO)

8

Role: Co-Investigator. Goal: To train and evaluate WHO field workers in the area of public health preparedness in response to the Ebola epidemic. Several training and evaluation methods were used including group consensus methods and case studies involving Ebola hazard vulnerability and risk assessments methods.

7/2015 – 6/2016 Developing Measures for Disaster Resiliency in Multiethnic and Linguistically Diverse Communities

Harvard Chan Internal Funding Sponsor: McLennan Dean’s Challenge Grant Program, Harvard University

Role: Principle Investigator Goal: To develop self-reported health status measures for evaluating

outcomes post-disaster in multiethnic and linguistically diverse communities.

Direct: $50,000 Indirect: $0 Total $50,000 10/2015 -3/2018 Program Evaluation of the “Three Cities” Countering Violent Extremism

Initiatives 2015-ST-108-FRG005 Sponsor: the U.S. Department of Homeland Security (DHS), Science & Technology Directorate, Resilient Systems Division Role: Co-Investigator Goal: To evaluate the “Three Cities” federally-funded programs developed by cities with the aid of community groups, religious groups, mental health and social service providers, educators and other NGOs that build prevention programs addressing the root causes of violent extremism and deter individuals who may already be radicalizing to violence.

1/2016 – 12/2016 The Evidence Based Preparedness Project – Synthesis and Translation of

Public Health Preparedness and Response Research 2016-ASPPH/CDC- S5045 Sponsor: ASPPH/CDC Role: Principal Investigator Goal: To conduct a knowledge synthesis and catalogue of products produced by the CDC-sponsored academic Preparedness and Emergency Response Research Centers (PERRC) Direct: $341,333 Indirect: $153,599 Total $494,932

1/2016 – 8/2017 Translation, Dissemination, and Implementation of Evidenced-based

Public Health Tools and Trainings 2016-ASPPH/CDC- S5052

9

Sponsor: ASPPH/CDC Role: Principal Investigator Goal: To develop and apply novel methods for the translation, dissemination, and implementation of evidenced-based public health tools and trainings. Direct: $745,183 Indirect: $335,332 Total $1,080,515

10/2016-09/2018 Evaluation of the Peer to Peer Initiative 2016-ZA-BX-K001

Sponsor: Institute of Justice, United States Department of Justice Role: Co-Investigator Goal: To assess the effectiveness of online counter narratives developed by youth to counter violent extremism in the United States.

ACTIVE GRANTS 10/2013 – 2/2019 Benchmarking the Comparative Effectiveness of Diabetes Treatments

Using Patient-Reported Outcomes and Socio-demographic Factors Sponsor: Patient Centered Outcomes Research Institute (PCORI) Role: Principal Investigator Goal: To develop models to benchmark the comparative effectiveness of

diabetes treatment using patient-reported outcomes and socio-demographic variables using randomized clinical trials pooled data, electronic health records and social media analytics

Direct: $1,655,345 Indirect: $369,901 Total $2,025,246 10/2018 – 10/2020 Evaluation Support for Countering Violent Extremism at the Local Level

Sponsor: North Atlantic Treatment Organization (NATO) and the U.S. Department of Homeland Security Science and Technology Directorate Role: Co-Investigator Goal: To help NATO and DHS evaluate their programs on countering terrorist threats faced by NATO allies and partner countries.

1/2019 – 9/2020 National Academies Study on Evidence-Based Practices for Public Health

Emergency Preparedness and Response Sponsor: National Academy of Science, Engineering and Medicine Role: Principal Investigator Goal: To inform NASEM’s deliberations regarding the evidence base for

the 15 capabilities listed in CDC’s Public Health Preparedness Capabilities: National Standards for State and Local Planning. The author(s) will conduct a review and evidence mapping of academic and gray literature that examines and describes the extent and nature of the

10

research conducted on practices that fall within the 15 PHEP capabilities since September 11, 2001.

Direct:$60,000 Total: $60,000 12/2018 - 12/2019 Developmental Project: The impact of nicotinamide mononucleotide (NMN) treatment on self-reported function and wellbeing in older men with functional limitations. Sponsor: Boston Claude D. Pepper Older Americans Independence Center (through an NIH Center Grant from the National Institute of Aging to Brigham and Women’s Hospital. Role: Principal Investigator Goal: To establish the validity of a patient-reported clinical outcome assessment measures that demonstrates improvement in fatigue and well- being so that it can be used as a co-primary endpoint in a Phase 2 trial of NMN. Total: $70,000 PENDING GRANTS (Under Review) 12/2018 – 11/2019 The Development of a Monitoring and Evaluation Methodology for Public Health Emergency Preparedness Sponsor: European CDC - University of Bologna as prime Role: Principal Investigator Goal: To assist the European CDC in evaluation of public health emergency preparedness programs. TEACHING AND TRAINING: TEACHING IN HARVARD CHAN SCHOOL COURSES As Primary Instructor

• BIO 200s, Principles of Biostatistics (1994, 95, 96, 97, 98, 99, 2000, 2001) (2.5 cr.)

• BIO 201ab, Introduction to Statistical Methods (1991, 92, 93, 94) (5 cr.)

• BIO 202/BST 202 Session 1, Principles of Biostatistics (2002, 2003, 2004, 2005, 2006,

2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018) (2.5 cr.)

• BIO 203ab, Statistical Methods for Health Policy and Management (1987, 88) (5 cr.)

• BIO 210cd, Rates and Proportions (1996) (5 cr.)

11

• BIO 211, Regression and Analysis of Variance in Experimental Research, 2013, 2014,

2015

• Bio 523/BST 217: Statistical and Quantitative Methods for Pharmaceutical Regulatory

Science (2014, 2015, 2016, 2017, 2018, 2019, 2020) (Spring 2, 2.5 credits)

• BIO 218d, Database Systems and Architecture (1988, 89, 90, 91) (2.5 cr)

• BIO 219ab, Statistical Methods for Health Policy and Management (1995, 96, 97, 98,

99) (5 cr.)

• BIO 262cd, Statistical Problems in Drug Development (1990, 92, 94, 96, 98, 99) (2.5cr)

• EPB 253c, Information Management and Data Resources for Epidemiology (2000, 2001,

2002) (2.5 cr.)

• HCP 502, Medical Decision Making and Clinical Epidemiology (1988, 89, 90, 91, 92)

• HPM 514, Developing Questionnaires for Measuring the Outcomes of Health Care

(2005) (2.5 credits)

• HPM 530, Measuring and Analyzing the Outcomes of Health Care (2006, 2007, 2008,

2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018) (2.5 credits)

• ID 253c, Information Management in Epidemiology (2003, 2004) (2.5 credits)

• ID 265/360, Practice of Quantitative Methods (1999, 2000, 2001, 2002, 2003, 2004,

2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018)

(2.5 cr.)

• ID 945A and ID 945B Practicum and Culminating Experience for Quantitative Methods

(2018, 2019)

• ID 945C Practicum and Culminating Experience for Quantitative Methods: Advanced

Methods (2019, 2020)

• ID 270/370, MPH Quantitative Methods Practicum (2000, 2001, 2002, 2003, 2004, 2005,

2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018) (5 cr.)

• ID 538 Foundations of Public xcHealth (2008) (10 cr.) – responsible for Local Public

Health Case Study and Biostatistics Requirement

As Invited Lecturer (Selected titles for one or more sessions)

• Bio 269cd, Psychiatric Statistics (1992-94)

12

• ID 265bc, Practice of Quantitative Methods (1995, 96, 97, 98)

• Human Phenotyping, Scholars in Clinical Science Program, Harvard Medical School

(2000, 01)

• Bio 287, Public Health Surveillance (2008, 2009, 2010, 2012, 2013)

• TIMI Grand Rounds, Harvard Medical School, (2008)

• HSPH-HMS 214x Fundamentals of Clinical Trials (2013-14)

• Pharmaceutical and Regulatory Sciences Workshop, Measurement and Analysis of

Quality-of-Life Outcomes for Drug Development, Workshop Organizing Chair and

Lecturer (May 2013)

• Harvard T.H. Chan School-Takeda Symposium, Patient Oriented Benefit Risk Evaluation

in Oncology (May 2015)

TEACHING IN EXECUTIVE AND CONTINUING EDUCATION COURSES

• Measurement, Design and Analysis Methods for Outcomes Research (1997, 1998, 1999,

2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013,

2014, 2015, 2016, 2017, 2018, 2019), Harvard Chan Center for Executive Continuing

Professional Education, 28 CME credit hours, Course Director.

• Outcomes Research (June 1997, 98, 99, 2000), Mediterranean School of Medical

Statistics and Clinical Epidemiology, Department of Biostatistics and Harvard Chan

Center for Executive Continuing Professional Education, 21 CME credit hours, Faculty.

• Outcomes Research (June 2003), Summer School on Modern Methods in Biostatistics

and Epidemiology (Treviso, Italy) Harvard Chan and Karolinska Institute, Sweden,

Course Director.

• Quality of Life and Pharmacoeconomics in the Treatment of Diabetes. (June 1996),

Harvard Chan Center for Executive Continuing Professional Education, 2 CME credit

hours, Course Director.

• Costs and Benefits of Diabetes Treatment: A Health-economics Perspective (June 1997,

Harvard Chan Center for Executive Continuing Professional Education, 2 CME credit

hours, Course Director.

13

• The Harvard Conference on American Conference on Health Care: Using Outcomes

Research to Evaluate and Manage Quality and Cost-Effectiveness of Health Care – a One

Day Workshop (November 2000, 2001, 2002), Course Director

• Lecturer on Health Outcomes Research Measurement, Patient Satisfaction and Trust – 2 -

3 Harvard Chan Executive Continuing Education Programs organized by David Shore

each year (2000, 2001, 2002, 2003), Course Director

• Statistical Issues in Drug Development, Kitasato University, 30 hours, Course Director

October 2007)

TEACHING IN OTHER COURSES WITHIN HARVARD Harvard Medical School HCP 502, Medical Decision Making and Clinical Epidemiology (1988, 89, 90, 91, 92) ADVISORY AND SUPERVISORY RESPONSIBILITIES

Harvard Chan Master of Public Health in Quantitative Methods

As the primary instructor in the Practicum and Culminating Experience courses (ID 265, ID 360, ID 270, ID 370 and ID 945) since 1999 and Co-Director/Director of the MPH QM Regular Program/MPH-QM Summer Only degree programs I have served as a practicum advisor for 40 - 45 MPH students per year. For several of these students, I have also served as the primary preceptor for their practicum project. A total of 509 MPH QM projects have been undertaken since 2006.

Doctoral Thesis Advisor: Harvard Chan Sc.D. Degree Program

Dates Name of trainee Type of supervision Current position

1989-90 Carolyn Schwartz Doctoral Committee (ScD) President and Chief Scientist Health and Social Behavior DeltaQuest Foundation, Inc. Concord, MA 1991-95 Susan Andrade Doctoral Committee (ScD) Professor, University of Epidemiology Massachusetts Medical School Pharmacoepidemiology Worcester, MA 1992- 95 Susan Oliveira Doctoral Committee (ScD) Director, Epidemiology and Epidemiology Drug Safety, IQVIA Pharmacoepidemiology (formerly Qunitiles)

14

1993-95 Sharon Milberger Doctoral Committee (ScD) Director Epidemiology Developmental Disabilities Psychiatric Epidemiology Institute, Wayne State Univ. 1996-99 Hideki Hashimoto Doctoral Committee (ScD) Professor, Sch of Public Health Health and Social Behavior Behavioral Health Sciences Tokyo University 1998-2000 Constance G. Bacon Doctoral Committee (ScD) Boston, MA Health and Social Behavior 1995 – 2000 Kristen Snow Doctoral Committee (ScD) Health Data Specialist Epidemiology New Hampshire Dept HHS 1998 -2002 Maxwell Su Doctoral Committee (ScD) Research Associate Biostatistics Biostatistics, Harvard Chan 1999 – 2003 Yinong Young-Xu Doctoral Committee (ScD) Director Epidemiology Clinical Epidemiology White River Junction, VA Medical Center, Veterans Health Administration 2000 – 2002 Chen-Chang Yang Doctoral Committee Professor & Chair Institute (MPH, DPH) of Environmental & Pharmacoepidemiology Occupational Health Sciences School of Medicine, National Yang-Ming University Taiwan R.O.C. 2001 – 2005 Linda G. Marc Doctoral Committee (ScD) National Implementation Health and Social Behavior Director Fenway Institute, Boston 2002 – 2006 Allison Smitten Doctoral Committee (ScD) Medical Director (GPV&E) Epidemiology Medical Safety Assessment Pharmacoepidemiology Bristol Myers Squibb 2014-2016 Ryan Calder Doctoral Committee (ScD) Postdoctoral Associate Environmental Health Duke University Pratt School of Engineering

15

INVITED PRESENTATIONS: (Since 2013)

Does not include oral or poster presentations at scientific meetings – see published abstract section for those presentations. 11/5/2013 - Measurement, mechanistic and geospatial models of public health hazard vulnerability and jurisdictional risk. Applied Statistics Section, Annual American Public Health Association Meeting, Boston, 2013. 11/2/2013 - Lessons of Hurricane Sandy. 18th Annual Certificate Program, Massachusetts Association of Health Boards, Marlborough, MA, 2013. 11/16/2013 - Lessons of Hurricane Sandy. 18th Annual Certificate Program, Massachusetts Association of Health Boards, Taunton, MA, 2013 11/1/2014 - The 2014 West Virginia Water Crisis: A Case Study on Public Communication, Reactions and Implications for Policy. 19th Annual Certificate Program, Massachusetts Association of Health Boards, Taunton, MA, 2014 11/15/2014 - The 2014 West Virginia Water Crisis: A Case Study on Public Communication, Reactions and Implications for Policy. 19th Annual Certificate Program, Massachusetts Association of Health Boards, Marlborough, MA, 2014. 11/7/2015 - Ready for the Next Snow Emergency. Learning from the Past Severe Weather Emergencies in Massachusetts and Planning Ahead. 20th Annual Certificate Program, Massachusetts Association of Health Boards, Marlborough, MA, 2015. 11/14/2015 - Ready for the Next Snow Emergency. Learning from the Past Severe Weather Emergencies in Massachusetts and Planning Ahead. 20th Annual Certificate Program, Massachusetts Association of Health Boards, Marlborough, MA, 2015. 11/5/2016 - What is the Role of Public Health in Addressing Violence Perpetrated in the Name of an Ideology? 21st Annual Certificate Program, Massachusetts Association of Health Boards, Taunton, MA, 2016. 11/5/2016 - What works in public health preparedness? What we know works in emergency risk communication, 21st Annual Certificate Program, Massachusetts Association of Health Boards, Taunton, MA, 2016. 11/5/2016 - A Case Study of Strengthening Community Involvement in Public Health: Wellesley Board of Health Preserves an Independent Board of Health. 21st Annual Certificate Program, Massachusetts Association of Health Boards, Taunton, MA, 2016.

16

11/12/2016 - What is the Role of Public Health in Addressing Violence Perpetrated in the Name of an Ideology? 21st Annual Certificate Program, Massachusetts Association of Health Boards, Marlborough, MA, 2016. 11/12/2016 - What works in public health preparedness? What we know works in emergency risk communication. 21st Annual Certificate Program, Massachusetts Association of Health Boards, Marlborough, MA. 11/12/2016 - A Case Study of Strengthening Community Involvement in Public Health: Wellesley Board of Health Preserves an Independent Board of Health. 21st Annual Certificate Program, Massachusetts Association of Health Boards, Marlborough, MA. 6/12/2017 - Health Disparities Among Patients with Diabetes Can Be Improved by New Approaches and Insights, American Diabetes Association, San Diego, CA 11/4/2017 - Gathering Local Knowledge in Preparedness from Vulnerable Populations. 22nd Annual Certificate Program, Massachusetts Association of Health Boards, Marlborough, MA, 2017. 11/18/2017 - Gathering Local Knowledge in Preparedness from Vulnerable Populations, Boards of Health 2017 22nd Annual Certificate Program, Massachusetts Association of Health Boards, Taunton, MA. 4/24/2018 - Committee on Evidence-Based Practices for Public Health Emergency Preparedness and Response, National Academy of Science, Engineering and Medicine, Washington, D.C. 11/10/18 - Violence and Youth Health. 23rd Annual Certificate Program, Massachusetts Association of Health Boards, Taunton, MA. 11/17/18 - Violence and Youth Health. 23rd Annual Certificate Program, Massachusetts Association of Health Boards, Marlborough, MA, 2018 11/2/19 – Food Inspection Staffing. 24rd Annual Certificate Program, Massachusetts Association of Health Boards, Marlborough, MA, 2019 11/16/19 – Food Inspection Staffing. 11/16/19 – Food Inspection Staffing. 24rd Annual Certificate Program, Massachusetts Association of Health Boards, Taunton, MA, 2019

17

COMMUNITY SERVICE ACTIVITIES

2004 - Vice Chair Wellesley Board of Health (Elected) Town of Wellesley, MA

2016 - Town Meeting Member (Elected) Town of Wellesely, MA

2004 Medical Research Corps (MRC) Volunteer1 Norfolk County-7 MRC

2006 - Member League of Women Voters

2004 - Executive Committee Member Massachusetts Association of Health Boards 2016 Chairman Massachusetts Association of Health Boards 2017 - Liaison to Massachusetts Office of Local Massachusetts Association of and Regional Public Health, Massachusetts Health Boards Department of Public Health

The Medical Reserve Corps (MRC) is a national network of volunteers, organized locally to improve the health and safety of their communities. The MRC network comprises approximately 190,000 volunteers in 900 community-based units located throughout the United States and its territories.

BIBLIOGRAPHY:

1. Peer-Reviewed Publications A. Original Research

A list of my peer-reviewed publications can be found at http://www.ncbi.nlm.nih.gov/sites/myncbi/marcia.testa.1/bibliography/46072918/public/?sort=date&direction=descending

1. Desiderato O, and Testa MA. Shock stress, gastric secretions and habituations in the chronic fistula rat. Physiol Behav. 1976 Jan;16(1):67-73. PubMed PMID: 944928.

2. Testa MA and Meigs JW. Mathematical modeling of cancer incidence rates: Linear models of colon cancer in Connecticut. J Chronic Dis. 1980;33(11-12):733-43. PubMed PMID: 7430325.

3. Krishnamohan VK, Wheeler MB, Testa MA and Philipps AF. Correlation of postnatal regression of the anterior vascular capsule of the lens to gestational age. J Pediatr

18

Ophthalmol Strabismus. 1982 Jan-Feb;19(1):28-32. PubMed PMID: 7069563.

4. Holmes G, Rowe J, Hafford J, Schmidt R, Testa M and Zimmerman A. Prognostic value of the electroencephalogram in neonatal asphyxia. Electroencephalogr Clin Neurophysiol. 1982 Jan;53(1):60-72. PubMed PMID: 6173201.

5. Cieplinski W, Reardon P and Testa, MA. Non-random human chromosome distribution in human-mouse myeloma somatic hybrids. Cytogenet Cell Genet. 1983;35(2):93-9. PubMed PMID: 6851676.

6. Gettinger G, Patters MR, Testa MA, Loe H, Anerud A, Boysen H, and Robertson PB. The use of six selected teeth in population measures of periodontal status. J Periodontol. 1983 Mar;54(3):155-9. PubMed PMID: 6573472.

7. Dore-Duffy P, Catalanotto F, Donaldson JO, Ostrom KM and Testa MA. Zinc in multiple sclerosis. Ann Neurol. 1983 Oct;14(4):450-4. PubMed PMID: 6195958.

8. Levin RE, Testa MA, Weinstein A, Peterson M and Rothfield NF. A comparison of the sensitivity of the 1971 and 1982 American Rheumatism Association criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1984 May;27(5):530-8. PubMed PMID: 6721885.

9. KROC Collaborative Study Group (MA Testa, co-author). Blood glucose control and the evolution of diabetic retinopathy and albuminuria: A preliminary multicenter trial. N Engl J Med. 1984 Aug 9;311(6):365-72. PubMed PMID: 6377076.

10. Tanzer JM, Borjesson AC, Laskowski L, Kurasz AB and Testa M. Glucose- Sucrose-Potassium Tellurite-Bacitracin agar: An alternative to Mitis Salivarius-Bacitracin Agar for enumeration of Streptococcus mutans. J Clin Microbiol. 1984 Oct;20(4):653-9. PubMed PMID: 6490852; PubMed Central PMCID: PMC271404.

11. Catalanotto FA, Dore-Duffy P, Donaldson JO, Testa M, Peterson M and Ostrom KM. Quality-specific taste changes in multiple sclerosis. Ann Neurol. 1984 Nov;16(5):611-5. PubMed PMID: 6508242.

12. Lundy J, Thor A, Maenza R, Schlom J, Forouhar F, Testa M and Kufe D. Monoclonal antibody DF3 correlates with tumor differentiation and hormone receptor status in breast cancer patients. Breast Cancer Res Treat. 1985;5(3):269-76. PubMed PMID: 2992647.

13. Bartlett RC, Mazens MF and Testa MA. Differentiation of Psuedomonas aeruginosa and Enterobacteriaceae in direct smear based on measurements by scanning electron microscopy. Diagn Microbiol Infect Dis. 1985 Mar;3(2):143-7. PubMed PMID: 3919992.

14. Testa MA and Simonson DC. The design and structure of clinical research information systems: Implications for data retrieval and analysis. J Med Syst. 1985 Jun;9(3):109-19. PubMed PMID: 3840516.

15. Passas CM, Wong RL, Peterson M, Testa MA and Rothfield NF. A comparison of the specificity of the 1971 and 1982 American Rheumatism Association criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1985 Jun;28(6):620-3.

19

PubMed PMID: 4004972.

16. Testa MA, Puklin JE, Simonson DC and Sherwin RS. Clinical predictors of retinopathy and its progression in patients with Type I diabetes during continuous subcutaneous insulin infusion or conventional insulin treatment. Diabetes. 1985 Aug;34 Suppl 3:61-8. PubMed PMID: 3894129.

17. Kohner EM, Lawson PM, Ghosh G and Testa M. Assessment of angiograms. Diabetes. 1985 Aug;34 Suppl 3:56-60. PubMed PMID: 4018421.

18. Peterson MGE and Testa MA. Rank order scaling in taste evaluation. Comput Biomed Res. 1986 Feb;19(1):56-62. PubMed PMID: 3753915.

19. Croog SH, Levine S, Testa MA, Brown B, Bulpitt CJ, Jenkins CD, Klerman GL and Williams GH. The effects of antihypertensive therapy on the quality of life. N Engl J Med. 1986 Jun 26;314(26):1657-64. PMID: 3520318 DOI: 10.1056/NEJM198606263142602

20. Testa, MA: Quality of life during antihypertensive therapy: Techniques for clinical assessment and evaluation. Br J Clin Pharmacol. 1987;23 Suppl 1:9S-13S. PubMed PMID: 3580259; PubMed Central PMCID: PMC1386041.

21. Levine S, Croog SH, Sudilovsky A and Testa MA. Antihypertension and life satisfaction. Qual Life Cardiovasc Care 1987:3:26-28.

22. Williams GH, Croog SH, Levine S, Testa MA and Sudilovsky A. Impact of antihypertensive therapy on quality of life: Effect of hydrochlorothiazide. J Hypertens Suppl. 1987 Feb;5(1):S47-54. PubMed PMID: 3553496.

23. Croog SH, Levine S, Testa MA and Sudilovsky A. Work performance and antihypertensive medications: A comparison of captopril, methyldopa and propranolol. J Hypertension 1987;5(Suppl. 1):S47-S54. (PMID: 3553496)

24. Testa, MA. Interpreting quality of life clinical trial data for use in the clinical practice of antihypertensive therapy. J Hypertens Suppl. 1987 Feb;5(1):S9-13. PubMed PMID: 3553497.

25. Levine S, Croog SH, Sudilovsky A and Testa MA. Effects of antihypertensive medications on vitality and well-being. J Fam Pract. 1987 Oct;25(4):357-63. PubMed PMID: 3309131.

26. Testa MA and Simonson DC. Measuring quality of life in hypertensive patients with diabetes. Postgrad Med J. 1988;64 Suppl 3:50-8; discussion 90-2. PubMed PMID: 3249717.

27. Pinkerton RE, Garibaldi RA, Conrad C, Bush F, Brown DH, Testa MA, Mancini L, Lerer TJ, Ryan R, Aukerman G and Tilton R. Urinary tract symptoms in rural New England family practice: A microbiologic evaluation. J Am Board Fam Pract. 1988 Jan-Mar;1(1):39-45. PubMed PMID: 3414387.

28. Williams GH and Testa MA. Quality of life and its assessment in treating hypertension. Current Opinion in Cardiology 1988:3 (Supplement 1);577- 581.

20

29. KROC Collaborative Study Group (M. Testa, Co-author). Diabetic retinopathy after two years of intensified insulin treatment. Follow-up of KROC Collaborative Study. JAMA. 1988 Jul 1;260(1):37-41. PubMed PMID: 2898025

30. Spackman TJ, Peccei R, and Testa MA. Commercial research and development in times of financial restraint. Invest Radiol. 1988 Oct;23(10):791-4. PubMed PMID: 3192401.

31. Sudilovsky A, Croog SH, Crook T, Turnbull B, Testa MA, Levine S and Klerman GL. Differential effects of antihypertensive medications on cognitive functioning. Psychopharmacol Bull. 1989;25(1):133-8. PubMed PMID: 2772112.

32. Testa MA, Sudilovsky A, Rippey R and Williams GH: A short form for the clinical assessment of quality of life in hypertensive patients. Am J Prev Med. 1989 Mar-Apr;5(2):82-9. PubMed PMID: 2659046.

33. Schoenberger JA, Testa M, Ross AD, Brennan WK, Bannon JA. Efficacy, safety and quality of life assessment of captopril antihypertensive therapy in clinical practice. Archives of Internal Medicine. Arch Intern Med. 1990 Feb;150(2):301-6. PubMed PMID: 2405803.

34. Hollenberg NK, Testa M, and Williams, G. Quality of Life as a therapeutic endpoint: An analysis of therapeutic trials in Hypertension. Drug Saf. 1991 Mar-Apr;6(2):83-93. Review. PubMed PMID: 2043286.

35. Testa MA, Hollenberg NK, Anderson RA, Williams GH. Assessment of quality of life by patient and spouse during antihypertensive therapy with atenolol and nifedipine GITS. Am J Hypertens. 1991 Apr;4(4 Pt 1):363-73. PubMed PMID: 2059396.

36. Gelber RD, Lenderking WR, Cotton DJ, Cole B, Fischl MA, Goldhirsch A and Testa MA. Quality-of-life evaluation in a clinical trial of zidovudine therapy for patients with mildly symptomatic HIV infection. Ann Intern Med. 1992 Jun 15;116(12 Pt 1):961-6. PubMed PMID: 1586104.

37. Testa MA and Lenderking WR. Interpreting pharmacoeconomic and quality-of-life clinical trial data for use in therapeutics. Pharmacoeconomics. 1992 Aug;2(2):107-17. PubMed PMID: 10146951.

38. Testa MA. Parallel perspectives on quality of life during antihypertensive therapy: Impact of responder, survey environment and questionnaire structure. J Cardiovasc Pharmacol. 1993;21 Suppl 2:S18-25. PubMed PMID: 7692146.

39. Testa MA, Anderson RB, Nackley JF and Hollenberg NK: Quality of life and antihypertensive therapy in men: A comparison of captopril with enalapril, N Eng J Med. 1993 Apr 1;328(13):907-13. PubMed PMID: 8446137.

40. Testa MA, Nackley JF. Methods for quality-of-life studies. Annu Rev Public Health. 1994;15:535-59. Review. PubMed PMID: 8054098.

41. Anderson RB and Testa, MA. Symptom distress checklists as a component of quality-of-life measurement: Comparing prompted reports by patient and physician with concurrent

21

adverse event reports via the Physician. Drug Inf J 1994;28:89-114.

42. Parker JD, Testa MA, Jimenez AH, Tofler GH, Muller JE, Parker JO and Stone PH. Morning increase in ambulatory ischemia in patients with stable coronary artery disease: Importance of physical activity and increased cardiac demand. Circulation 1994 Feb;89(2):604-14. PubMed PMID: 8313548.

43. Lenderking WR, Gelber RD, Cotton DJ, Cole BF, Goldhirsch A, Volberding PA and Testa MA. Evaluation of quality of life associated with zidovudine therapy in asymptomatic human immunodeficiency virus infection. N Engl J Med. 1994 Mar 17;330(11):738-43. PubMed PMID: 7906386.

44. Anderson RB, Nackley JF, Testa MA. Symptom distress check lists as a component of quality of life measurement: Comparing symptom reports with responses to multiple choice questionnaires. Drug Inf J 1995; (1689S-1707S).

45. Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Sapieria GM, Platt R. Discontinuation of antihyperlipidemic drugs -- Do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 1995 Apr 27;332(17):1125-31. Review. PubMed PMID: 7700285.

46. Fuleihan GE, Testa MA, Angell JE, Porrino N, LeBoff MS. Reproducibility of dual-energy X-ray absorptiometry: A model for bone loss estimates. J Bone Miner Res. 1995 Jul;10(7):1004-14. PubMed PMID: 7484275.

47. Lenderking WR, Nackley JF, Anderson RB, Testa MA. A review of quality-of-life aspects of urinary urge incontinence. Pharmacoeconomics. 1996 Jan;9(1):11-23. Review. PubMed PMID: 10160084.

48. Testa MA and Simonson DC. Assessing quality-of-life outcomes. N Engl J Med. 1996 Mar 28;334(13):835-40. PubMed PMID: 8596551.

49. Testa MA. The Medical Outcomes Study. (Letter). 1996 Apr 10;275(14):1083; author reply 1084-5. PubMed PMID: 8601917.

50. Milberger S, Faraone SV, Biederman J, Testa M, Tsuang MT. New phenotype definition of attention deficit hyperactivity disorder in relatives for genetic analyses. Am J Med Genet. 1996 Jul 26;67(4):369-77. PubMed PMID: 8837705

51. Testa MA and Turner RR. Assessment of quality of life in hypertension and its bearing on compliance. International Journal of Clinical Practice 1997; Suppl. 92:19-22.

52. Kaplan LD, Straus DJ, Testa MA, Von Roenn J, Dezube BJ, Cooley TP, Herndier B, Northfelt DW, Huan J, Tulpule A, Levine A for the NIAID AIDS Clinical Trials Group. Randomized trial of standard-dose vs. Low-dose mBACOD chemotherapy for HIV-associated non-Hodgkin’s lymphoma. N Engl J Med. 1997 Jun 5;336(23):1641-8. PubMed PMID: 9171066.

53. Lenderking WR, Testa MA, Katsenstein D, Hammer S. Measuring quality of life in HIV disease: the modular approach. Qual Life Res. 1997 Aug;6(6):515-30. PubMed PMID:

22

9330552.

54. Krown SE, Testa M, Huang J. AIDS-related Kaposi’s Sarcoma: Prospective validation of the AIDS Clinical Trials Group staging system. J Clin Oncol. 1997 Sep;15(9):3085-92. PubMed PMID: 9294471.

55. Gill PS. Mitsuyasu RT, Montgomery T, Huang J. Cabriales S. Testa M, Espina BM, Levine AM, Miles SA. AIDS Clinical Trials Group Study 094: a phase I/II trial of ABV chemotherapy with zidovudine and recombinant human GM-CSF in AIDS-related Kaposi's sarcoma . Cancer J Sci Am. 1997 Sep-Oct;3(5):278-83. PubMed PMID: 9327151.

56. Carroll J, Testa MA, El-Hajj Fuleihan G. Modeling fracture risk using bone density, age and years since menopause. Am J Prev Med. 1997 Nov-Dec;13(6):447-52. PubMed PMID: 9415791.

57. Testa MA, Quality of life, adherence and antihypertensive therapy (In Japanese) . Presented at the 95th Japanese Society of Internal Medicine, Fukuoka, Japan. Circulation Insights, Life Sciences Publishing. Summer, 1998 (No. 2): 8-13.

58. Straus DJ, Huang J, Testa MA, Levine AM and Kaplan LD. Prognostic factors in the treatment of human immunodeficiency virus --Associated non-hodgkin's lymphoma. Analysis of AIDS Clinical Trials Group Protocol 142 -- low dose vs. standard dose m-BACOD plus granulocyte-macrophage colony stimulating factor. J Clin Oncol. 1998 Nov;16(11):3601-6. PubMed PMID: 9817281.

59. Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: A randomized controlled, double-blind trial. JAMA. 1998 Nov 4;280(17):1490-6. PubMed PMID: 9809729.

60. Testa MA, Simonson DC, Turner RR. Valuing quality of life and improvements in glycemic control in people with type 2 diabetes. Diabetes Care. 1998 Dec;21 Suppl 3:C44-52. PubMed PMID: 9850489.

61. Testa MA, Turner RR, Krafcik MB, Simonson DC, Calvo C, Luque-Otero M. and the Nifedipine GITS Study Group. Quality of life and calcium channel blockade with nifedipine GITS versus amlodipine in hypertensive patients in Spain. J Hypertens. 1998 Dec;16(12 Pt 1):1839-47. PubMed PMID: 9869019.

62. Testa MA and Lenderking WR. The impact of AIDS-associated wasting on quality of life: Qualitative issues of measurement and evaluation. J Nutr. 1999 Jan;129(1S Suppl):282S-289S. doi: 10.1093/jn/129.1.282S. PubMed PMID: 9915916.

63. Lenderking WR, Tennen H, Nackley JF, Hale MS, Turner RR , Testa MA. Effects of venlafaxine on social activity level in depressed outpatients. J Clin Psychiatry. 1999 Mar;60(3):157-63. PubMed PMID: 10192590.

64. Rabkin CS, Testa MA, Huang J, Von Roenn JH. Kaposi's Sarcoma and non-hodgkin's lymphoma incidence trends in AIDS Clinical Trials Group Study Partcipants. J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S31-3. PubMed PMID: 10430216.

23

65. Blonde L, Dey J, Testa MA, Guthrie D. Defining and measuring quality of diabetes care. Prim Care. 1999 Dec;26(4):841-55. Review. PubMed PMID: 10523463.

66. Testa MA. Quality-of-life assessment in diabetes research: Interpreting the magnitude and meaning of treatment effects. Diabetes Spectrum 2000:13; 29-35.

67. Turner RR and Testa MA. Measuring the impact of onychomycosis on patient quality of life. Qual Life Res. 2000 Feb;9(1):39-53. PubMed PMID: 10981205.

68. Testa MA. Interpretation of quality of life outcomes: Issues that affect magnitude and meaning. Med Care. 2000 Sep;38(9 Suppl):II166-74. PubMed PMID: 10982103.

69. Langley PC, Testa MA. Can you measure the quality of this life? Interview by Lauren M. Walker. Bus Health. 2000 Oct;18(9):42-4, 47-8. PubMed PMID: 11141794.

70. Testa MA. Methods and applications of quality-of-life measurement during antihypertensive therapy. Curr Hypertens Rep. 2000 Dec;2(6):530-7. Review. PubMed PMID: 11062598.

71. Bacon CG, Giovannucci E, Testa M, Kawachi I. The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. J Urol. 2001 Nov;166(5):1804-10. PubMed PMID: 11586228.

72. Bacon CG, Giovannucci E, Testa M, Glass TA, Kawachi I. The association of treatment-related symptoms with quality-of-life outcomes for localized prostate carcinoma patients. Cancer. J Interferon Cytokine Res. 2002 Mar;22(3):295-303. PubMed PMID: 12034036.

73. Krown SE, Li P, Von Roenn JH, Paredes J, Huang J and Testa MA. Efficacy of low –dose interferon with antiretroviral therapy in Kaposi’s sarcoma: A randomized Phase II AIDS Clinical Trials Group Study. J Interferon Cytokine Res. 2002 Mar;22(3):295-303. PubMed PMID: 12034036.

74. Evans SR. Krown SE. Testa MA. Cooley TP. Von Roenn JH. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study. J Clin Oncol. 2002 Aug 1;20(15):3236-41. PubMed PMID: 12149296.

75. Miles SA, Testa M, Huang J, Wade M, Carden J, Scadden DT. Lack of antitumor activity and intolerance of interleukin-4 in patients with advanced HIV disease and Kaposi's sarcoma. J Interferon Cytokine Res. 2002 Nov;22(11):1143-8. PubMed PMID: 12513914.

76. Testa, MA. Improving diabetes therapy: Improving satisfaction. Diabetes Voice 2003; 48: 23 – 25.

77. Yang CC, Jick SS, Testa MA. Who receives lipid-lowering drugs: the effects of comorbidities and patient characteristics on treatment initiation. Br J Clin Pharmacol. 2003 Mar;55(3):288-98. PubMed PMID: 12630980; PubMed Central PMCID: PMC1884220.

78. Yang CC, Jick SS, Testa MA. Discontinuation and switching of therapy after initiation of lipid-lowering drugs: the effects of comorbidities and patient characteristics. Br J Clin Pharmacol. 2003 Jul;56(1):84-91. PubMed PMID: 12848779; PubMed Central PMCID:

24

PMC1884321.

79. Chou SC, Heather Palmer R, Ezhuthachan S, Newman C, Pradell-Boyd, B, Maisels J, Testa MA. Management of Hyperbilirubinemia in Newborns: Measuring Performance by Using a Benchmarking Model. Pediatrics. 2003 Dec;112(6 Pt 1):1264-73. PubMed PMID: 14654595.

80. Savoia E, Morano J, Cote D, Rampal S, Villa D, Testa MA. Public health preparedness evaluation and measurement. Italian Journal of Public Health. 2004;1(1-2):56.

81. Reynolds NR, Testa MA, Marc L, Chesney MA Neidig JL, Smith SR, Vella S, Robbins GK for the Protocol Teams of ACTG 384, ACTG 731 and A5031s. Factors influencing medication adherence beliefs and self-efficacy in persons naïve to antiretroviral therapy: a multi-center, cross-sectional study. AIDS Behav. 2004 Sep;114(3):902. PubMed PMID: 15342881

82. Palmer RH, Ezhuthachan S, Newman C, Maisels MJ, Testa MA. Hyperbilirubinemia benchmarking. Pediatrics. 2004 Sep;114(3):902. PubMed PMID: 15342881

83. Palmer RH, Ezhuthachan S, Newman C, Maisels MJ, Testa MA. Management of hyperbilirubinemia in newborns: measuring performance using a benchmarking model. Pediatrics. 2004 Sep;114(3):902-4. PubMed PMID: 15342882.

84. Fletcher CV, Testa MA, Brundage RC, Chesney MA, Haubrich R, Acosta EP, Martinez A, Jiang H, Gulick RM. Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359. J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):301-6. PubMed PMID: 16249704.

85. Beal AC, Chou SC, Palmer RH, Testa MA, Newman C, Ezhuthachan S. Related Articles, The changing face of race: risk factors for neonatal hyperbilirubinemia. Pediatrics. 2006 May;117(5):1618-25. PubMed PMID: 16651315.

86. Straus DJ, Testa MA, Sarokhan BJ, Czuczman MS, Tulpule A, Turner RT, Riggs SA. Treatment of Mild Anemia: a Randomized Trial of Epoetin Alfa in Patients Receiving Chemotherapy for Hematologic Malignancies, Cancer. 2006 Dec;118(6):2424-33. PubMed PMID: 17142528.

87. Meaney PA, Nadkarni VM, Cook EF, Testa M, Helfaer M, Kaye W, Larkin GL, Berg RA; American Heart Association National Registry of Cardiopulmonary Resuscitation Investigators. Higher survival rates among younger patients after pediatric intensive care unit cardiac arrests. Pediatrics. 2006 Dec;118(6):2424-33. PubMed PMID: 17142528.

88. Dorn BC, Savoia E, Testa MA, Stoto MA, Marcus LJ. Development of a survey instrument to measure connectivity to evaluate national public health preparedness and response performance. Public Health Rep. 2007 May-Jun;122(3):329-38. PubMed PMID: 17518304; PubMed Central PMCID: PMC1847495.

89. Testa MA, Simonson DC. Satisfaction and quality of life with premeal inhaled versus injected insulin in adolescents and adults with type 1 diabetes. Diabetes Care. 2007 Aug;63(2):207-16. PubMed PMID: 17662759.

25

90. Marc LG, Testa MA, Walker AM, Robbins GK, Shafer RW, Anderson NB, Berkman LF; ACTG Data Analysis Concept Sheet Study Team. Educational attainment and response to HAART during initial therapy for HIV-1 infection. J Psychosom Res. 2007 Aug;63(2):207-16. PubMed PMID: 17662759.

91. Smitten AL, Choi HK Hochberg MC, Suissa A, Simon TA, Testa MA, Chan KA. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum. 2007 Dec 15;57(8):1431-8. PubMed PMID: 18050184.

92. Reynolds NR, Testa MA, Su M, Chesney MA, Neidig JL, Frank I, Smith S, Ickovics J, Robbins GK; for the AIDS Clinical Trials Group 731 and 384 Teams. Telephone support to improve antiretroviral medication adherence: A multisite, randomized controlled trial. J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):62-8.( PMID: 17891043)

93. Smitten AL, Choi HK Hochberg MC, Suissa A, Simon TA, Testa MA, Chan KA. The risk of hospitalized infection in patients with rheumatoid arthritis. 2008 Mar;35(3):387-93. Epub 2008 Feb 1. PubMed PMID: 18260176.

94. Savoia E, Testa MA, Biddinger PD, Cadigan RO, Koh H, Campbell P, Stoto MA. Assessing public health capabilities during emergency preparedness tabletop exercises: reliability and validity of a measurement tool. Public Health Rep. 2 2009 Jan-Feb;124(1):138-48. PubMed PMID: 19413036; PubMed Central PMCID: PMC2602939.

95. Bode B, Testa MA, Magwire M, Hale PM, Hammer M, Blonde L, Garber A. Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes. Diabetes Obes Metab. 2010; 2010 Jul;12(7):604-12. doi: 10.1111/j.1463-1326.2010.01196.x. PubMed PMID: 20590735; PubMed Central PMCID: PMC2901519.

96. Henderson E, Testa MA, Hartnick C. Prevalence of noise-induced hearing-threshold shifts and hearing loss among US youths. Pediatrics 2011 Jan;127(1):e39-46. doi: 10.1542/peds.2010-0926. Epub 2010 Dec 27. PubMed PMID: 21187306.

97. Marc LG, Zerden M, Ferrando S, Testa MA. HIV+ caregivers and HIV+ non-caregivers: differences in sociodemographics, immune functioning and quality-of-life. AIDS Care. 2011 Oct;147(10):1159-65. doi: 10.1001/archdermatol.2011.184. PubMed PMID: 22006132.

98. Bailey EE, Marghoob AA, Orengo IF, Testa MA, White VR, Geller AC. Skin cancer knowledge, attitudes, and behaviors in the salon: a survey of working hair professionals in Houston, Texas. Arch Dermatol. 2011 Oct;147(10):1159-65. doi: 10.1001/archdermatol.2011.184. PubMed PMID: 22006132.

99. Marc LG, Wang, MM, Testa MA. Psychometric evaluation of the HIV symptom distress scale. AIDS Care. 2012 AIDS Care. 2012;24(11):1432-41. doi: 10.1080/09540121.2012.656567. Epub 2012 Mar 12. PubMed PMID: 22409246; PubMed Central PMCID: PMC3436989.

100. Savoia E, Testa MA, Viswanath V. Predictors of knowledge of H1N1 infection and

26

transmission in the U.S. population. BMC Public Health. 2012 May 3;12:328. doi: 10.1186/1471-2458-12-328. PubMed PMID: 22554124; PubMed Central PMCID: PMC3436710.

101. Nanda A, Khan IS, Goldman R, Testa M.. Sports-related concussions and the Louisiana Youth Concussion Act. J La State Med Soc. 2012 Sep-Oct;164(5):246-50. PubMed PMID: 23362587.

102. Testa MA, Gill J, Su M, Turner RR, Blonde L and Simonson DC. Comparative effectiveness of basal-bolus versus premix analogue insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: A randomized, controlled, cross-over trial. J Clin Endocrinol Metab. 2012 Oct;97(10):3504-14. doi: 10.1210/jc.2012-1763. Epub 2012 Jul 31. PubMed PMID: 22851487.

103. Robbins GK, Testa MA, Su M, Safren SA, Morse G, Lammert S, Shafer RW, Reynolds NR, Chesney MA. Site nurse-initiated adherence and symptom support telephone calls for HIV-positive individuals starting antiretroviral therapy, ACTG 5031: substudy of ACTG 384. HIV Clin Trials. 2013 Sep-Oct;14(5):235-53. doi: 10.1310/hct1405-235. PubMed PMID: 24144900; PubMed Central PMCID: PMC4019013.

104. Turner RR, Testa MA, Hayes JF, and Su M. Validation of the allergic rhinitis treatment satisfaction and preference scale. Allergy Asthma Proc. 2013 Nov-Dec;34(6):551-7. doi: 10.2500/aap.2013.34.3715. Epub 2013 Sep 27. PubMed PMID: 24079817.

105. Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM, Cohen DJ, Matsumoto AH, Steffes M, Jaff MR, Prince MR, Lewis EF, Tuttle KR, Shapiro JI, Rundback JH, Massaro JM, D'Agostino RB Sr, Dworkin LD; CORAL Investigators. (M Testa – CORAL Investigator). Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med. 2014 Jan 2;370(1):13-22. doi: 10.1056/NEJMoa1310753. Epub 2013 Nov 18. PubMed PMID: 24245566; PubMed Central PMCID: PMC4815927.

106. Testa MA, Pettigrew ML and Savoia E. Measurement, geospatial, and mechanistic models of Public Health Hazard Vulnerability and Jurisdictional Risk, Journal of Public Health Management and Practice, J Public Health Manag Pract. 2014 Sep-Oct;20 Suppl 5:S61-8. doi: 10.1097/PHH.0000000000000079. PubMed PMID: 25072492.

107. Marc LG, Henderson WR, Desrosiers A, Testa MA, Jean SE, Akom EE. Reliability and Validity of the Haitian Creole PHQ-9. J Gen Intern Med. 2 2014 Dec;29(12):1679-86. doi: 10.1007/s11606-014-2951-5. Epub 2014 Aug 5. PubMed PMID: 25092004; PubMed Central PMCID: PMC4242883

108. Doshi-Velez F, Marshall YE, Lasry D, Testa MA, Su M, Konate S, Torres J Savoia E et al. Humanitarian Technology: Science, Systems and Global Impact 2015, HumTech2015HackEbola with Data: On the hackathon format for timely data analysis. HackEbola with Data. Procedia Engineering. 2015 107:377 - 386.

109. DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, Hu FB, Kahn CR, Raz I, Shulman GI, Simonson DC, Testa MA, Weiss R. Type 2 diabetes mellitus. Nat

27

Rev Dis Primers. 2015 Jul 23;1:15019. doi: 10.1038/nrdp.2015.19. Review. PubMed PMID: 27189025.

110. Jendle J, Testa MA, Martin S, Jiang H, Milicevic Z. Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy. Diabetes Obes Metab. 2016 Oct;18(10):999-1005. doi: 10.1111/dom.12705. Epub 2016 Jul 22. PubMed PMID: 27279266.

111. Okubo Y, Nochioka K, Hataya H, Sakakibara H, Terakawa T, Testa M. Burden of Obesity on Pediatric Inpatients with Acute Asthma Exacerbation in the United States. J Allergy Clin Immunol Pract. 2016 Nov - Dec;4(6):1227-1231. doi: 10.1016/j.jaip.2016.06.004. Epub 2016 Jun 30. PubMed PMID: 27372599.

112. Okubo Y, Nochioka K, Sakakibara H, Hataya H, Terakawa T, Testa M, Sundel RP. Nationwide epidemiological survey of childhood IgA vasculitis associated hospitalization in the USA. Clin Rheumatol. 2016 Nov;35(11):2749-2756. Epub 2016 Sep 5. PubMed PMID: 27596741.

113. Okubo Y, Nochioka K, Sakakibara H, Testa M, Sundel RP. National survey of pediatric hospitalizations due to Kawasaki disease and coronary artery aneurysms in the USA. Clin Rheumatol. 2017 Feb;36(2):413-419. doi: 10.1007/s10067-016-3512-6. Epub 2016 Dec 16. PubMed PMID: 27987089.

114. O’Neill RT and Testa MA. Let’s Go to the Videotape: Promoting the visibility and understanding of regulatory science by using case studies from publicly available FDA information. Chance. 2017;30(1): 4-14: http://chance.amstat.org/2017/02/videotape/.

115. Okubo Y, Nochioka K, Testa MA. Nationwide Survey of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children in the United States. Pediatr Dermatol. 2017 Mar;34(2):206-208. doi: 10.1111/pde.13050. Epub 2016 Dec 19. PubMed PMID: 27990674.

116. Ouchi K, Hohmann S, Goto T, Ueda P, Aaronson EL, Pallin DJ, Testa MA, Tulsky JA, Schuur JD, Schonberg MA. Index to predict in-hospital mortality in older adults after non-traumatic emergency department intubations. West J Emerg Med. 2017 Jun;18(4):690-697. doi: 10.5811/westjem.2017.2.33325. Epub 2017 Apr 19. PubMed PMID: 28611890; PubMed Central PMCID: PMC5468075.

117. Okubo Y, Nochioka K, Testa M. Nationwide survey of pediatric acute osteomyelitis in the USA. J Pediatr Orthop B. 2017 Nov;26(6):501-506. doi: 10.1097/BPB.0000000000000441. PubMed PMID: 28230612.

118. O'Toole A, de Silva PS, Marc LG, Ulysse CA, Testa MA, Ting A, Moss A, Korzenik J, Friedman S. Sexual Dysfunction in Men With Inflammatory Bowel Disease: A New IBD-Specific Scale. Inflamm Bowel Dis. 2018 Jan 18;24(2):310-316. doi: 10.1093/ibd/izx053. PubMed PMID: 29361102; PubMed Central PMCID: PMC6014620.

119. Epstein S, Tran BN, Capone AC, Ruan QZ, Fukudome EY, Ricci JA, Testa MA,

28

Dennerlein JT, Lee BT, Singhal D. The current state of surgical ergonomics education in U.S. surgical training: A survey study. Ann Surg. 2018 Jan 29. doi: 10.1097/SLA.0000000000002592. [Epub ahead of print] PubMed PMID: 29381528.

120. Okubo Y, Nochioka K, Testa MA. The impact of pediatric obesity on hospitalized children with lower respiratory tract infections in the United States. Clin Respir J. 2018 Apr;12(4):1479-1484. doi: 10.1111/crj.12694. Epub 2017 Sep 7. PubMed PMID: 28842971.

121. Turchin A, Sosina O, Zhang H, Shubina M, Desai SP, Simonson DC, Testa MA. Ambulatory Medication Reconciliation and Frequency of Hospitalizations and Emergency Department Visits in Patients With Diabetes. Diabetes Care. Diabetes Care. 2018 Aug;41(8):1639-1645. doi: 10.2337/dc17-1260. Epub 2018 Jun 11. PubMed PMID: 29891639.

122. Okubo Y, Nochioka K, Testa MA. Nationwide Survey of Hospitalization Due to Pediatric Food-Induced Anaphylaxis in the United States. Pediatr Emerg Care. 2018 Aug 14. doi: 10.1097/PEC.0000000000001543. [Epub ahead of print] PubMed PMID: 30113437

123. de Silva PS, O'Toole A, Marc LG, Ulysse CA, Testa MA, Julsgaard M, Ngyuen D, Ananthakrishnan A, Laursen T, Højgaard A, Christensen LA, Korzenik J, Friedman S. Development of a Sexual Dysfunction Scale for Women With Inflammatory Bowel Disease. Inflamm Bowel Dis. Inflamm Bowel Dis. 2018 Oct 12;24(11):2350-2359. doi: 10.1093/ibd/izy202. PubMed PMID: 30165525.

124. Savoia E, Guicciardi S, Bernard DP, Harriman N, Leinhos M and Testa M. Preparedness Emergency Response Research Centers (PERRCs): Addressing Public Health Preparedness Knowledge Gaps Using a Public Health Systems Perspective. Am J Public Health. 2018 Nov;108(S5):S363-S365. doi: 10.2105/AJPH.2018.304812. PubMed PMID: 30422694; PubMed Central PMCID: PMC6236718.

125. Testa MA, Savoia E, Su M, Biddinger PD. Social Media Learning Collaborative for Public Health Preparedness. Am J Public Health. Am J Public Health. 2018 Nov;108(S5):S375-S377. doi: 10.2105/AJPH.2018.304610. Epub 2018 Sep 27. PubMed PMID: 30260697; PubMed Central PMCID: PMC6236724.

126. Minegishi M, Takahashi T, Testa M. Pediatric acquired demyelinating syndrome (ADS) in inpatient hospital settings: The hospitalization rate, costs, and outcomes in the US. Mult Scler Relat Disord. 2019 Jun 27;34:150-157. doi: 10.1016/j.msard.2019.06.031. [EpuPMID: 31295724

127. Zhang H, Goldberg SI., Hosomura N, Shubina M, Simonson DC, Testa MA, Turchin A. Lifestyle Counseling and Long-term Clinical Outcomes in Patients With Diabetes. Diabetes Care Aug 1;. doi: 10.2337/dc19-0629. [Epub ahead of print] PubMed PMID: 31371430.

128. Fozouni L, Buchheit B, Walley AY, Testa M, Chatterjee A. Public restrooms and the opioid epidemic. Subst Abus. 2019 Aug 1;:1-5. doi: 10.1080/08897077.2019.1640834.

29

[Epub ahead of print] PubMed PMID: 31368865. DOI

129. Frias JP, Gonzalez-Galvez G, Johnsson E, et al. Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial. Diabetes Obes Metab. 2020. (Accepted 2/12/2020)

2. Non-peer reviewed publications (including books and monographs)

1. Testa MA and Spencer RP. Monitoring of kinetic in vivo radiopharmaceutical data:

Linear models analysis of Michaelis-Menten parameters. In Interventional Nuclear Medicine (RP Spencer, Ed.), Grune and Stratton, pp. 609-610, 1984.

2. Williams GH and Testa MA. Quality of life: An important consideration in antihypertensive therapy. In Management of Hypertension: A Multifactorial Approach (NK Hollenberg, Ed.), Scientific Therapeutics Information, Butterworth Publishers, Stoneham, MA, 1987, pp. 79-100.

3. Testa MA and Lenderking WR. Quality of life considerations in clinical trials of persons with HIV infection" in AIDS Clinical Trials (Eds., Finkelstein D and Schoenfeld D), Wiley-Liss,New York, 1995, pp 213-241.

4. Max S and Testa MA. A Latent Variable Growth Model Approach to Analyzing Multiple Health Outcomes from Clinical Trials pages 113 – 138 Book Chapter 6 in Advancing Health Outcomes Research Methods and Clinical Applications (Eds) William R. Lenderking & Dennis A. Revicki, 386 pages; ISBN 0-9656837-4-5, 386pp.

5. Testa M and Simonson D. The Use of Questionnaires and Surveys. In: Robertson D and Williams G Clinical and Translational Sciences. London: Elsevier. 2009 Chapter 9, pp 137-153.

6. Testa M and Simonson D. The Use of Questionnaires and Surveys. In: Robertson D and Williams G Clinical and Translational Sciences, 2nd Edition. London: Elsevier. 2017 Chapter 9, pp 207 – 226.

7. Cook EA and Testa MA. Quality of Health Care. In The Diabetic Foot: Medical and Surgical Management (Third Edition). Part IV Organization and Preventive Care. Chapter 24. Veves A, Giurini JM and LoGerfo FW (Eds). Springer, New York, 2012 pp. 481 – 502.

8. Testa MA. Quality of Health Care. In The Diabetic Foot: Medical and Surgical Management (Fourth Edition). Part IV Organization and Preventive Care. Chapter 24. Veves A, Giurini JM and Guzman RJ (Eds). Humana Press, Springer International Publishing AG, part of Springer Nature, Switzerland, 2018 pp. 447 – 470.

30

3. Educational Materials

Preparedness and Emergency Response Learning Center (PERLC) and Harvard Chan Emergency Preparedness, Research, Evaluation and Practice Tools and Trainings (EPREP). Role: As the Principal Investigator of the CDC-Sponsored Harvard Chan PERLC and the current Co-Director of the EPREP program, I have been responsible for developing a workforce curriculum of educational trainings and tools for local, state and tribal public health agencies in the area of public health and emergency preparedness. Selected examples of PERLC and EPREP developed training content is currently available online as listed below:

a) PERLC and EPREP Educational Programs

https://www.hsph.harvard.edu/preparedness/education

b) Preparedness and Emergency Response Research Center (PERRC) Inventory: https://www.hsph.harvard.edu/preparedness/toolkits/perrcs-toolkit-inventory/

c) National Association of Country and City Health Officials (NACCHO Toolbox) • How to Learn from the Response to Critical Incidents

http://toolbox.naccho.org/pages/tool-view.html?id=5180 • How to Exercise for Hazardous Materials Incident http://toolbox.naccho.org/pages/tool-

view.html?id=5187 • How to Exercise Hospital Evacuation http://toolbox.naccho.org/pages/tool-

view.html?id=5188 • How to Exercise Hospital Surge http://toolbox.naccho.org/pages/tool-view.html?id=5189 • How to Evaluate Performance During Exercise http://toolbox.naccho.org/pages/tool-

view.html?id=5190 How to Create Surveys to Assess Public Communication • http://toolbox.naccho.org/pages/tool-view.html?id=5193 • How to Teach Kids about Non-Pharmaceutical Interventions

http://toolbox.naccho.org/pages/tool-view.html?id=5194 • How to Plan for Alternate Care Sites http://toolbox.naccho.org/pages/tool-

view.html?id=5195

d) TRAIN.org (Official online training site of the CDC) • Emergency Planning for Local Public Health

https://www.train.org/main/course/1037309/ • Module 1: Introduction to CHEMPACK https://www.train.org/main/course/1037608/ • Public Communication of Risk in 21st Century: Promises and Challenges

https://www.train.org/main/course/1037639/ • Using Exercises to Enhance and Measure Preparedness

https://www.train.org/main/course/1037635/ • Case Study: The Great Springfield Tornado https://www.train.org/main/course/1037637/

31

• Exercise Evaluator Training https://www.train.org/main/course/1064932/ • Module 2: CHEMPACK Response Procedures for Nerve Agent Incidents

https://www.train.org/main/course/1037631/ • Module 3: Logistics & Maintenance of the CHEMPACK Containers

https://www.train.org/main/course/1037632/ • Public Health and the Incident Command System

https://www.train.org/main/course/1046620/

4. Published abstracts (since 2013)

1. Testa MA and Simonson DC. Socioeconomic and Demographic Predictors of Internet and Social Media Use in Persons with Diabetes. Diabetes 2013; 62 Supplement 1.

2. Testa MA, Gill G, Su M, Traylor L, and Simonson D. CGM and SMBG Analytics Predict Hypoglycemic Risk and Symptoms during Intensive Insulin Titration. Diabetes 2014; 63 Supplement 1.

3. Testa MA and Simonson DC. Development of a Personalized, Patient-Centered Glycemic Control Benchmarking Tool for T2DM. A303. Diabetes 2014; 63 Supplement 1.

4. Testa MA, Turchin A, Sosina OA, Simonson DC. Benchmarking T2DM Treatment Effectiveness in Clinical Practice. Diabetes 2015; 64 Supplement 1: A346, 1330-P.

5. Simonson DC, Marc LG, Testa MA. Health Education Internet Use by Persons with Diabetes in the US. Diabetes 2015; 64 Supplement 1; A159, 770-P.

6. Testa MA, Saldivar-Salazar A, Savoia E, Simonson D. Using Social Media Crowdsourced Data for Diabetes Patient-Centered Outcomes Research (PCOR). A55. Diabetes 2015; 64 Supplement 1; A55, 220-OR.

7. Testa MA and Ayan Jha. Development of Simulation and Structural Equation Models for Public Health Hazard Vulnerability and Jurisdictional Risk Analysis. Atlanta, GA, 2015.

8. Testa MA, Su M, Turchin A, Simonson DC. Patient-Centered Outcomes and Socio-Demographic Predictors of Diabetes Treatment Effectiveness. Diabetes 2016; 65 Supplement 1; A324, 1235-P.

9. Testa MA, Marc LG, Turchin A, Simonson DC. Impact of Subclinical Depression and Anxiety on Intensity and Frequency of Treatment-Related Side Effects and Symptoms. Diabetes 2016; 65 Supplement 1; A211, 823-P.

10. Turchin A, Sosina O, Zhang H, Shubina M, Desai SP, Simonson DC, Testa MA. Effect of Medication Reconciliation on Emergency Department Visits and Hospitalizations in Patients with Diabetes. Diabetes 2016; 65 Supplement 1; A319, 1216-P.

11. Zhang H, Hosomura N, Shubina M, Simonson DC, Testa MA, Turchin A. Electronic Documentation of Lifestyle Counseling in Primary Care Is Associated with Lower Risk of Cardiovascular Events in Patients with Diabetes. Diabetes 2016; 65 Supplement 1; A363,

32

1387-P.

12. Saldivar-Salazar S, Testa MA, Hayes JF, Simonson DC. Effectiveness of real-time assessment of non-calibrated CGM data to determine the need for repeat CGM in a blinded clinical trial. Diabetes 2017 Jun; 66 (Supplement 1): A245, 950-P.

13. Testa MA and Simonson DC. Health Disparities Among Patients with Diabetes Can Be Improved by New Approaches http://www.diabetes.org/newsroom/press-releases/2017/health-disparities-scientific-sessions-2017.html (Accessed October 15, 2017).

14. Testa MA, Saldivar-Salazar S, Su M, Marc LG, Simonson DC. A social media learning collaborative approach to competency-based training in diabetes. Diabetes 2017 Jun; 67 (Supplement 1): A97, 368-OR.

15. Testa MA and Su M. Design and Architecture of a Social Media Learning Collaborative for the Translation and Dissemination of Preparedness Trainings and Tools. NACCHO Preparedness Summit, Atlanta, GA, 2017.

16. Testa MA, Saldivar-Salazar, S, Su M, Simonson DC. Continuous Glucose Monitoring (CGM) Provides Enhanced Sensitivity Compared with Self-Monitored Blood Glucose (SMBG) for Detecting Hypoglycemia during T2D Clinical Trials. Diabetes 2018; 67 Supplement 1, 941-P A244.

17. Testa MA, Turchin A, Su M, Simonson DC. Impact of Patient-Centered Factors on Comparative Effectiveness of Initial Therapies in Treatment-Naïve T2D. Diabetes 2018; 67 Supplement 1, 1520-P A407.

18. Testa MA, Simonson DC, Ekholm E, Su M, Johnsson EK. Patient-reported outcomes in T2D patients inadequately controlled by metformin are more favorable for dapagliflozin plus saxagliptin vs. insulin glargine. Diabetes 2018; 67 Supplement 1, 810-P A211.

19. Simonson DC, Vilsbøll T, Ekholm E, Johnsson EK, Testa M, Jabbour S, Lind M. Continuous Glucose Monitoring Glycemic Variability Profiles Are More Favorable for Dapagliflozin plus Saxagliptin Compared with Insulin Glargine in Type 2 Diabetes. Diabetes 2018; 67 Supplement 1, 905-P A235.

20. Simonson DC, Testa MA, Maaske J, Garcia-Sanchez R, Johnsson E, Su M, Frias JP. Continuous glucose monitoring glycaemic profiles are more favourable for dapagliflozin plus saxagliptin compared to glimepiride when added to metformin in type 2 diabetes. 54th EASD Annual Meeting of the European Association for the Study of Diabetes, Berlin Germany, Diabetologia October 2018; 61 (Supplement 1), 643, S312.

21. Testa MA, Hayes JF, Lind M, Vilsbøl T, Jabbour S, Ekholm E, Johnsson E, D.C. Simonson. Durability of improved patient-reported outcomes in type 2 diabetes patients treated with dapagliflozin plus saxagliptin vs insulin. 54th EASD Annual Meeting of the European Association for the Study of Diabetes, Berlin Germany, Diabetologia October 2018; 61 (Supplement 1), 830, S408.

22. Testa MA, Su M, Simonson DC. Modeling Pathways between Psychological Distress, Emergent Symptoms and Side Effects, and Endpoint A1C during Treatment. Diabetes 2019;

33

68 Supplement 1,850-P, https://doi.org/10.2337/db19-850-P.

23. Saldivar-Salazar S, Testa MA, Hayes JF, Simonson DC. Causes of Blinded CGM Failure during Clinical Trials in Patients with T2D. Diabetes 2019; 68 Supplement 1, 302-OR, https://diabetes.diabetesjournals.org/content/68/Supplement_1/302-OR